Steve Duffy

Digital Content Editor

Most Recent Articles by Steve Duffy

Ready-to-Use Rescue Pen for Severe Hypoglycemia Moves Closer to Approval

By Feb 16, 2018

The full findings of the trials will not be released until later this year however the Company stated that the trials were a success, with the data already shared with the FDA in a pre-New Drug Application (NDA) meeting.

Rituxan Granted Priority Review for Rare Autoimmune Disease

By Feb 16, 2018

The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.

Oral JAK1 Inhibitor Gets Breakthrough Tx Designation for Atopic Dermatitis

By Feb 15, 2018

In December, a Phase 3, randomized, double-blind, placebo-controlled trial (JADE) was initiated to evaluate the safety and efficacy of PF-04965842 in 375 patients aged ≥12 years with moderate to severe AD.

FDA Accepts NDA for Plaque Psoriasis Treatment Jemdel

By Feb 14, 2018

Jemdel, if approved, will be the first high-potency topical steroid for plaque psoriasis with dosing for 8 weeks. The most common adverse event in clinical trials of Jemdel was upper respiratory tract infection.

Depression Treatment Initiation Among Newly Diagnosed 'Suboptimal', Says Study

By Feb 13, 2018

A total of 241,251 adults with newly diagnosed depression were assessed for this study.

More Articles by Steve Duffy